Theodosios D Filippatos (Theodosios Filippatos)

Scopus Author ID Loop profile ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 27

Top Venues

Nutrients

Journal of cardiovascular pharmacology and therapeutics

Viruses

Diabetes, metabolic syndrome and obesity : targets and therapy

University of Crete School of Medicine

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Crete School of Medicine Dec 17 2017

Greece

Assistant Professor :: Internal Medicine

Publications

Antonia Pagkali, Anastasios Makris, Kalliopi Brofidi, Aris P Agouridis, Theodosios D Filippatos
Pathophysiological Mechanisms and Clinical Associations of Non-Alcoholic Fatty Pancreas Disease. Diabetes, metabolic syndrome and obesity : targets and therapy 17 (2024)
Antonia Pagkali, Anastasios Makris, Kalliopi Brofidi, Aris P Agouridis, Theodosios D Filippatos
Pathophysiological Mechanisms and Clinical Associations of Non-Alcoholic Fatty Pancreas Disease. Diabetes, metabolic syndrome and obesity : targets and therapy 17 (2024)
Petros Ioannou, Athanasios Katsigiannis, Ioanna Papakitsou, Ioannis Kopidakis, Eirini Makraki, Dimitris Milonas, Theodosios D Filippatos, Georgios Sourvinos, Marina Papadogiannaki, Evaggelia Lydaki, Georgios Chamilos, Diamantis P Kofteridis
Convalescent Plasma Treatment of Patients Previously Treated with B-Cell-Depleting Monoclonal Antibodies Suffering COVID-19 Is Associated with Reduced Re-Admission Rates. Viruses 15 (3) (2023)
Ioannis Akoumianakis, Anastasios Zagaliotis, Maria Konstantaraki, Theodosios D Filippatos
GLP-1 analogs and regional adiposity: A systematic review and meta-analysis. Obesity reviews : an official journal of the International Association for the Study of Obesity (2023)
Eleni A Karavia, Panagiota C Giannopoulou, Vassiliki Konstantinopoulou, Katerina Athanasopoulou, Theodosios D Filippatos, Demosthenes B Panagiotakos, Kyriakos E Kypreos
Medicines for Obesity: Appraisal of Clinical Studies with Grading of Recommendations, Assessment, Development, and Evaluation Tool. Nutrients 15 (3) (2023)
Eleni A Karavia, Panagiota C Giannopoulou, Vassiliki Konstantinopoulou, Katerina Athanasopoulou, Theodosios D Filippatos, Demosthenes B Panagiotakos, Kyriakos E Kypreos
Medicines for Obesity: Appraisal of Clinical Studies with Grading of Recommendations, Assessment, Development, and Evaluation Tool. Nutrients 15 (3) (2023)
Petros Ioannou, Athanasios Katsigiannis, Ioanna Papakitsou, Ioannis Kopidakis, Eirini Makraki, Dimitris Milonas, Theodosios D Filippatos, Georgios Sourvinos, Marina Papadogiannaki, Evaggelia Lydaki, Georgios Chamilos, Diamantis P Kofteridis
Convalescent Plasma Treatment of Patients Previously Treated with B-Cell-Depleting Monoclonal Antibodies Suffering COVID-19 Is Associated with Reduced Re-Admission Rates. Viruses 15 (3) (2023)
Eleni A Karavia, Panagiota C Giannopoulou, Vassiliki Konstantinopoulou, Katerina Athanasopoulou, Theodosios D Filippatos, Demosthenes B Panagiotakos, Kyriakos E Kypreos
Medicines for Obesity: Appraisal of Clinical Studies with Grading of Recommendations, Assessment, Development, and Evaluation Tool. Nutrients 15 (3) (2023)
Petros Ioannou, Athanasios Katsigiannis, Ioanna Papakitsou, Ioannis Kopidakis, Eirini Makraki, Dimitris Milonas, Theodosios D Filippatos, Georgios Sourvinos, Marina Papadogiannaki, Evaggelia Lydaki, Georgios Chamilos, Diamantis P Kofteridis
Convalescent Plasma Treatment of Patients Previously Treated with B-Cell-Depleting Monoclonal Antibodies Suffering COVID-19 Is Associated with Reduced Re-Admission Rates. Viruses 15 (3) (2023)
Elena Valeria Fuior, Evangelia Zvintzou, Theodosios D Filippatos, Katerina Giannatou, Victoria Mparnia, Maya Simionescu, Anca Violeta Gafencu, Kyriakos E Kypreos
Peroxisome Proliferator-Activated Receptor α in Lipoprotein Metabolism and Atherosclerotic Cardiovascular Disease. Biomedicines 11 (10) (2023)
Eleni A Karavia, Panagiota C Giannopoulou, Vassiliki Konstantinopoulou, Katerina Athanasopoulou, Theodosios D Filippatos, Demosthenes B Panagiotakos, Kyriakos E Kypreos
Medicines for Obesity: Appraisal of Clinical Studies with Grading of Recommendations, Assessment, Development, and Evaluation Tool. Nutrients 15 (3) (2023)
Petros Ioannou, Despoina Spentzouri, Myrto Konidaki, Michalis Papapanagiotou, Sotiris Tzalis, Ioannis Akoumianakis, Theodosios D Filippatos, Symeon Panagiotakis, Diamantis P Kofteridis
COVID-19 in Older Individuals Requiring Hospitalization. Infectious disease reports 14 (5) (2022)
Ioannis Akoumianakis, Evangelia Zvintzou, Kyriakos Kypreos, Theodosios D Filippatos
ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets. Current atherosclerosis reports 23 (5) (2021)
Petros Ioannou, Symeon Panagiotakis, Emmanouela Tsagkaraki, Constantinos Tsioutis, Konstantinos Fragkiadakis, Achilleas Gikas, Theodosios D Filippatos
Increased Mortality in Elderly Patients Admitted with Hyponatremia: A Prospective Cohort Study. Journal of clinical medicine 10 (14) (2021)
Theodosios D Filippatos
Non-Alcoholic Fatty Pancreas Disease: A Diagnosis of Increasing Importance. Angiology (2021)
Eliza Christopoulou, Vasilios Tsimihodimos, Theodosios D Filippatos, Moses Elisaf
Apolipoprotein CIII and diabetes. Is there a link? Diabetes/metabolism research and reviews 35 (3) (2019)
Eleni Pappa, Christos V Rizos, Theodosios D Filippatos, Moses S Elisaf
Emerging Fixed-Dose Combination Treatments for Hyperlipidemia. Journal of cardiovascular pharmacology and therapeutics 24 (4) (2019)
Eliza Christopoulou, Moses Elisaf, Theodosios D Filippatos
Effects of Angiopoietin-Like 3 on Triglyceride Regulation, Glucose Homeostasis, and Diabetes. Disease markers 2019 (2019)
Ioanna Papakitsou, George Vougiouklakis, Moses S Elisaf, Theodosios D Filippatos
Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes. Clinical pharmacology : advances and applications 11 (2019)
Theodosios D Filippatos, Thalia Panagiotopoulou, Eleftheria Tzavella, Moses S Elisaf
Hypolipidemic Drugs and Diabetes Mellitus-Mechanisms and Data From Genetic Trials. Journal of cardiovascular pharmacology and therapeutics 23 (3) (2018)
Sempastian Filippas-Ntekouan, Vasilios Tsimihodimos, Theodosios D Filippatos, Theodora Dimitriou, Moses S Elisaf
SGLT-2 inhibitors: pharmacokinetics characteristics and effects on lipids. Expert opinion on drug metabolism & toxicology 14 (11) (2018)
Theodosios D Filippatos, Moses S Elisaf, George Liamis
Pharmacological management of hyponatremia. Expert opinion on pharmacotherapy 19 (12) (2018)
Sebastian Filippas-Ntekouan, Theodosios D Filippatos, Moses S Elisaf
SGLT2 inhibitors: are they safe? Postgraduate medicine 130 (1) (2017)
Theodosios D Filippatos, Anastazia Kei, Moses S Elisaf
Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias? Diseases (Basel, Switzerland) 5 (4) (2017)
Theodosios D Filippatos, Eleftheria Tzavella, Christos V Rizos, Moses S Elisaf, George Liamis
Acid-base and electrolyte disorders associated with the use of antidiabetic drugs. Expert opinion on drug safety 16 (10) (2017)
Theodosios D Filippatos, Anastazia Kei, Christos V Rizos, Moses S Elisaf
Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid Variables. Journal of cardiovascular pharmacology and therapeutics 23 (1) (2017)
Christos V Rizos, Theodosios D Filippatos, Moses S Elisaf
Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetes. Expert opinion on drug metabolism & toxicology 14 (1) (2017)

Theodosios D Filippatos.css-eqlu8i{font-size:small;padding-left:4px;} (Theodosios Filippatos)

Publication Activity (10 Years)

Top Topics

Top Venues

Theodosios D Filippatos (Theodosios Filippatos)